HUP0400300A2 - Pyrrolopyrimidines as protein kinase inhibitors - Google Patents
Pyrrolopyrimidines as protein kinase inhibitorsInfo
- Publication number
- HUP0400300A2 HUP0400300A2 HU0400300A HUP0400300A HUP0400300A2 HU P0400300 A2 HUP0400300 A2 HU P0400300A2 HU 0400300 A HU0400300 A HU 0400300A HU P0400300 A HUP0400300 A HU P0400300A HU P0400300 A2 HUP0400300 A2 HU P0400300A2
- Authority
- HU
- Hungary
- Prior art keywords
- pyrrolopyrimidines
- protein kinase
- kinase inhibitors
- inhibitors
- protein
- Prior art date
Links
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
- 150000004944 pyrrolopyrimidines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0115393.1A GB0115393D0 (en) | 2001-06-23 | 2001-06-23 | Chemical compounds |
US30167801P | 2001-06-28 | 2001-06-28 | |
PCT/GB2002/002835 WO2003000695A1 (en) | 2001-06-23 | 2002-06-21 | Pyrrolopyrimidines as protein kinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0400300A2 true HUP0400300A2 (en) | 2007-08-28 |
HUP0400300A3 HUP0400300A3 (en) | 2010-12-28 |
Family
ID=9917225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0400300A HUP0400300A3 (en) | 2001-06-23 | 2002-06-21 | Pyrrolopyrimidines as protein kinase inhibitors |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP1404676A1 (hu) |
JP (1) | JP4344607B2 (hu) |
CN (1) | CN1294135C (hu) |
AU (1) | AU2002314325B8 (hu) |
BR (1) | BR0210652A (hu) |
CA (1) | CA2451932C (hu) |
CZ (1) | CZ20033443A3 (hu) |
EA (1) | EA007415B1 (hu) |
EC (1) | ECSP034922A (hu) |
EE (1) | EE05432B1 (hu) |
GB (1) | GB0115393D0 (hu) |
HU (1) | HUP0400300A3 (hu) |
ME (1) | MEP19308A (hu) |
NZ (1) | NZ529766A (hu) |
OA (1) | OA12632A (hu) |
PL (1) | PL374096A1 (hu) |
RS (1) | RS51698B (hu) |
SK (1) | SK15882003A3 (hu) |
TN (1) | TNSN03144A1 (hu) |
TR (1) | TR200302242T2 (hu) |
UA (1) | UA76760C2 (hu) |
WO (1) | WO2003000695A1 (hu) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0202679D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
MXPA05001096A (es) | 2002-07-29 | 2005-11-23 | Rigel Pharmaceuticals Inc | Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina. |
MXPA06005578A (es) | 2003-11-17 | 2006-08-11 | Pfizer Prod Inc | Compuestos de pirrolopirimidina utiles en el tratamiento del cancer. |
JP2007512316A (ja) * | 2003-11-25 | 2007-05-17 | ファイザー・プロダクツ・インク | アテローム性動脈硬化症の治療方法 |
WO2005105788A1 (en) * | 2004-04-23 | 2005-11-10 | Takeda San Diego, Inc. | Indole derivatives and use thereof as kinase inhibitors |
FR2876103B1 (fr) * | 2004-10-01 | 2008-02-22 | Aventis Pharma Sa | Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
ATE479687T1 (de) | 2004-10-15 | 2010-09-15 | Takeda Pharmaceutical | Kinaseinhibitoren |
FR2878849B1 (fr) | 2004-12-06 | 2008-09-12 | Aventis Pharma Sa | Indoles substitues, compositions les contenant, procede de fabrication et utilisation |
JP2008543855A (ja) | 2005-06-13 | 2008-12-04 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 変形性骨疾患を処置するための方法および組成物 |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
DK2348023T5 (da) | 2005-12-13 | 2017-05-15 | Incyte Holdings Corp | Heteroaryl-substituerede pyrrolo[2,3-b]pyridiner og pyrrolo[2,3-b]pyrimidiner som Janus-kinase-inhibitorer |
GEP20135728B (en) | 2006-10-09 | 2013-01-25 | Takeda Pharmaceuticals Co | Kinase inhibitors |
RS53245B2 (sr) | 2007-06-13 | 2022-10-31 | Incyte Holdings Corp | Soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo(2,3-d) pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropan-nitrila |
EA201070841A1 (ru) | 2008-01-11 | 2011-02-28 | Натко Фарма Лимитед | НОВЫЕ ПИРАЗОЛО[3,4-d]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПРОТИВОРАКОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ |
CA2727032C (en) | 2008-06-10 | 2018-08-14 | Abbott Laboratories | Tricyclic compounds |
EP2432472B1 (en) | 2009-05-22 | 2019-10-02 | Incyte Holdings Corporation | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
AU2010249380B2 (en) | 2009-05-22 | 2015-08-20 | Incyte Holdings Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus kinase inhibitors |
WO2011018894A1 (en) * | 2009-08-10 | 2011-02-17 | Raqualia Pharma Inc. | Pyrrolopyrimidine derivatives as potassium channel modulators |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
WO2011029043A1 (en) | 2009-09-04 | 2011-03-10 | Biogen Idec Ma Inc. | Heteroaryl btk inhibitors |
RU2570416C9 (ru) | 2009-12-01 | 2019-11-25 | Эббви Инк. | Имидазопирролопиразиновые производные, полезные для лечения заболеваний, вызванных аномальной активностью протеинкиназ Jak1, Jak3 или Syk |
SI3354652T1 (sl) | 2010-03-10 | 2020-08-31 | Incyte Holdings Corporation | Derivati piperidin-4-il azetidina kot inhibitorji JAK1 |
MY178634A (en) | 2010-05-21 | 2020-10-19 | Incyte Corp | Topical formulation for a jak inhibitor |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
JP5917545B2 (ja) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Jak阻害剤としてのシクロブチル置換ピロロピリジンおよびピロロピリミジン誘導体 |
CN103476776B (zh) * | 2011-01-07 | 2016-09-28 | 北京赛林泰医药技术有限公司 | 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物 |
CN102093364B (zh) | 2011-01-07 | 2015-01-28 | 北京赛林泰医药技术有限公司 | 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物 |
EA201490042A1 (ru) | 2011-06-20 | 2014-10-30 | Инсайт Корпорейшн | Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
EP2838898B1 (en) | 2012-04-20 | 2017-01-18 | Advinus Therapeutics Limited | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
AR091079A1 (es) | 2012-05-18 | 2014-12-30 | Incyte Corp | Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak |
PL2877467T3 (pl) | 2012-07-26 | 2017-08-31 | Glaxo Group Limited | 2-(azaindolo-2-ylo)benzoimidazole jako inhibitory pad4 |
EP2892534B8 (en) | 2012-09-06 | 2021-09-15 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2014078486A1 (en) | 2012-11-15 | 2014-05-22 | Incyte Corporation | Sustained-release dosage forms of ruxolitinib |
KR102366356B1 (ko) | 2013-03-06 | 2022-02-23 | 인사이트 홀딩스 코포레이션 | Jak 저해제를 제조하기 위한 방법 및 중간생성물 |
MX2015012386A (es) | 2013-03-13 | 2016-02-03 | Abbvie Inc | Inhibidores de la cinasa cdk9. |
CN105189481A (zh) | 2013-03-13 | 2015-12-23 | 艾伯维公司 | 吡啶cdk9激酶抑制剂 |
MX2015012153A (es) | 2013-03-14 | 2015-12-01 | Abbvie Inc | Inhibidores de la quinasa pirrolopirimidina cdk9. |
WO2014139328A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors |
BR112015023187A2 (pt) | 2013-03-14 | 2017-07-18 | Abbvie Inc | inibidores de pirrolo[2,3 - b] piridina cdk9 kinase |
PE20220579A1 (es) | 2013-08-07 | 2022-04-20 | Incyte Corp | Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 |
CN104804001B9 (zh) * | 2014-01-24 | 2022-02-08 | 江苏柯菲平医药股份有限公司 | 4-取代吡咯并[2,3-d]嘧啶化合物及其用途 |
WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
BR112018007677A2 (pt) | 2015-10-16 | 2018-11-06 | Abbvie Inc. | processos para a preparação de (3s,4r)-3-etil-4-(3h-imidazo[1,2-a]pirrolo[2,3-e]-pirazin-8-il)-n-(2,2,2-trifluoroetil)pirrolidina-1-carboxamida e suas formas em estado sólido |
US11773106B2 (en) | 2015-10-16 | 2023-10-03 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11564922B2 (en) | 2017-03-09 | 2023-01-31 | Abbvie Inc. | Methods of treating crohn's disease and ulcerative colitis |
AU2018230500B2 (en) | 2017-03-09 | 2024-03-07 | Abbvie Inc. | Methods of treating Crohn's disease and ulcerative colitis |
WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
EP4086245A1 (en) | 2018-01-30 | 2022-11-09 | Incyte Corporation | Processes for preparing intermediates for the synthesis of a jak inhibitor |
SG11202009441PA (en) | 2018-03-30 | 2020-10-29 | Incyte Corp | Treatment of hidradenitis suppurativa using jak inhibitors |
AU2019353144B2 (en) | 2018-10-05 | 2023-11-16 | Annapurna Bio, Inc. | Compounds and compositions for treating conditions associated with APJ receptor activity |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2177925T3 (es) * | 1996-01-23 | 2002-12-16 | Novartis Ag | Pirrolopirimidinas y procedimientos para su preparacion. |
JP2000505109A (ja) * | 1996-11-27 | 2000-04-25 | ファイザー・インク | 縮合二環式ピリミジン誘導体 |
PA8474101A1 (es) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
IL139586A0 (en) * | 1998-06-19 | 2002-02-10 | Pfizer Prod Inc | PYRROLO [2,3-d] PYRIMIDINE COMPOUNDS |
NZ510587A (en) * | 1998-09-18 | 2003-11-28 | Abbott Gmbh & Co | 4-aminopyrrolopyrimidines as kinase inhibitors |
DZ3248A1 (fr) * | 1999-12-10 | 2001-06-14 | Pfizer Prod Inc | Composés à base de pyrrolo[2,3-d]pyrimidine |
-
2001
- 2001-06-23 GB GBGB0115393.1A patent/GB0115393D0/en not_active Ceased
-
2002
- 2002-06-21 PL PL02374096A patent/PL374096A1/xx not_active Application Discontinuation
- 2002-06-21 NZ NZ529766A patent/NZ529766A/en not_active IP Right Cessation
- 2002-06-21 JP JP2003507098A patent/JP4344607B2/ja not_active Expired - Fee Related
- 2002-06-21 CA CA002451932A patent/CA2451932C/en not_active Expired - Fee Related
- 2002-06-21 EP EP02740895A patent/EP1404676A1/en not_active Withdrawn
- 2002-06-21 BR BR0210652-3A patent/BR0210652A/pt not_active Application Discontinuation
- 2002-06-21 ME MEP-193/08A patent/MEP19308A/xx unknown
- 2002-06-21 AU AU2002314325A patent/AU2002314325B8/en not_active Ceased
- 2002-06-21 CN CNB028119320A patent/CN1294135C/zh not_active Expired - Fee Related
- 2002-06-21 WO PCT/GB2002/002835 patent/WO2003000695A1/en active Application Filing
- 2002-06-21 EA EA200400073A patent/EA007415B1/ru not_active IP Right Cessation
- 2002-06-21 TR TR2003/02242T patent/TR200302242T2/xx unknown
- 2002-06-21 EE EEP200400003A patent/EE05432B1/xx not_active IP Right Cessation
- 2002-06-21 RS YU99203A patent/RS51698B/en unknown
- 2002-06-21 TN TNPCT/GB2002/002835A patent/TNSN03144A1/en unknown
- 2002-06-21 SK SK1588-2003A patent/SK15882003A3/sk not_active Application Discontinuation
- 2002-06-21 OA OA1200300335A patent/OA12632A/en unknown
- 2002-06-21 CZ CZ20033443A patent/CZ20033443A3/cs unknown
- 2002-06-21 HU HU0400300A patent/HUP0400300A3/hu unknown
- 2002-06-21 UA UA2004010502A patent/UA76760C2/uk unknown
-
2003
- 2003-12-23 EC EC2003004922A patent/ECSP034922A/es unknown
Also Published As
Publication number | Publication date |
---|---|
ECSP034922A (es) | 2004-04-28 |
CA2451932C (en) | 2009-12-29 |
CA2451932A1 (en) | 2003-01-03 |
JP2005508300A (ja) | 2005-03-31 |
CN1518552A (zh) | 2004-08-04 |
TNSN03144A1 (en) | 2005-12-23 |
WO2003000695A1 (en) | 2003-01-03 |
MEP19308A (en) | 2010-06-10 |
RS99203A (en) | 2006-12-15 |
CZ20033443A3 (en) | 2004-03-17 |
SK15882003A3 (sk) | 2004-07-07 |
EP1404676A1 (en) | 2004-04-07 |
PL374096A1 (en) | 2005-09-19 |
AU2002314325B8 (en) | 2009-01-29 |
EE200400003A (et) | 2004-02-16 |
BR0210652A (pt) | 2004-08-10 |
CN1294135C (zh) | 2007-01-10 |
RS51698B (en) | 2011-10-31 |
WO2003000695A8 (en) | 2004-03-11 |
GB0115393D0 (en) | 2001-08-15 |
HUP0400300A3 (en) | 2010-12-28 |
EE05432B1 (et) | 2011-06-15 |
AU2002314325B2 (en) | 2009-01-08 |
EA200400073A1 (ru) | 2004-08-26 |
UA76760C2 (uk) | 2006-09-15 |
OA12632A (en) | 2006-06-14 |
EA007415B1 (ru) | 2006-10-27 |
TR200302242T2 (tr) | 2004-12-21 |
NZ529766A (en) | 2008-11-28 |
JP4344607B2 (ja) | 2009-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0400300A2 (en) | Pyrrolopyrimidines as protein kinase inhibitors | |
HK1068134A1 (en) | Pyrrolopyrimidines as protein kinase inhibitors | |
AU2003254053A8 (en) | Pyrazolopyrimidines as protein kinase inhibitors | |
IL141866A0 (en) | Pyrrolopyrimidines as protein kinase inhibitors | |
IL161516A0 (en) | Benzimidazoles useful as protein kinase inhibitors | |
AU2000240570A1 (en) | Pyrrolopyrimidines as tyrosine kinase inhibitors | |
EP1510210A4 (en) | IMMUNITY-CONTAINING PROTEIN KINASE HEMMER | |
AU2002334355A1 (en) | Protein tyrosine kinase inhibitors | |
IL208520A0 (en) | Akt protein kinase inhibitors | |
EP1377587A4 (en) | PROTEIN INHIBITORS PHOSPHATE | |
EP1543009A4 (en) | Pyrrolotriazine KINASE INHIBITORS | |
PL369728A1 (en) | Pyrrolopyrimidines as phosphodiesterase vii inhibitors | |
HK1057702A1 (en) | Triazole compounds useful as protein kinase inhibitors | |
IL174948A0 (en) | Imidazopyrazine tyrosine kinase inhibitors | |
AP2003002816A0 (en) | Pyrazole compounds useful as protein kinase inhibitors | |
AU2002357193A1 (en) | Thienopyrimidine compounds as protein tyrosine kinase inhibitors | |
AU2003254051A8 (en) | Pyrazolopyrimidines as kinase inhibitors | |
AU2002953255A0 (en) | Protein kinase inhibitors | |
AU2003261204A1 (en) | Pyrazolopyrimidines as kinase inhibitors | |
AU2001247882A1 (en) | Tricyclic protein kinase inhibitors | |
IL144583A0 (en) | Chimeric protein kinase inhibitors | |
AU2003260787A1 (en) | Protein kinases | |
AUPS251502A0 (en) | Protein kinase inhibitors | |
GB0101686D0 (en) | Cyclin dependent kinase inhibitors | |
IL145329A0 (en) | Protein tyrosine kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |